inspirator schreef op 1 maart 2019 00:24:
These 10 New Drugs Expected In 2019 Are On The Blockbuster Track
A series of drugs expected to launch in 2019 could become blockbuster drugs in the next five years, according to a recent report.
Inflammation: A Key Area For Blockbuster Drugs?
Inflammation drugs are expected to account for nearly half of that $18 billion-plus in 2024 sales from expected blockbuster drugs.
AbbVie (ABBV) and Gilead Sciences (GILD) with its partner Galapagos (GLPG) are going up against one another with experimental drugs called upadacitinib and filgotinib.
Both belong to a class known as janus kinase 1 inhibitors, or JAK1 inhibitors. These drugs aim to block a pathway tied to inflammation in the body.
AbbVie's upadacitinib is already under review at the FDA as a rheumatoid arthritis treatment. The pharma giant is also studying upadacitinib in eczema, Crohn's disease, psoriatic arthritis, ulcerative colitis and axial spondyloarthritis, a series of chronic inflammatory diseases.
Fastest Mover
Gilead and Galapagos are furthest along in testing filgotinib in rheumatoid arthritis, ulcerative colitis and Crohn's disease. But the duo is also looking at the JAK1 inhibitor as a potential treatment for eight other diseases.
EvaluatePharma estimates upadacitinib could bring in $2.18 billion in 2024 sales, with filgotinib trailing at $1.49 billion.
www.investors.com/news/technology/new...